Article citationsMore >>

Abdou Hassan W, Muqresh MA, Omer M. The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer. Cureus. 2022; 14(10): e30509.

has been cited by the following article:

Article

Tumor Markers of Colorectal Carcinoma: New Perspectives

1Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt

2Zoology Department, Faculty of Science, Tanta University, Tanta 31527, Egypt


Journal of Cancer Research and Treatment. 2024, Vol. 12 No. 1, 1-7
DOI: 10.12691/jcrt-12-1-1
Copyright © 2024 Science and Education Publishing

Cite this paper:
Ahmed M. Kabel, Shaimaa M. Kabel. Tumor Markers of Colorectal Carcinoma: New Perspectives. Journal of Cancer Research and Treatment. 2024; 12(1):1-7. doi: 10.12691/jcrt-12-1-1.

Correspondence to: Ahmed  M. Kabel, Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Email: ahmed.kabal@med.tanta.edu.eg

Abstract

Colorectal carcinoma (CRC) represents one of the most commonly diagnosed malignant tumors worldwide. In spite of the continuous progress in diagnostic and therapeutic tools, CRC significantly contributes to cancer-related deaths all over the world. Early detection and treatment of patients with CRC may have a positive impact on prognosis, as the delay of diagnosis carries the risk of poor prognosis. Recently, new tumor biomarkers were discovered which can alone or together with the existing tests recognize either the predisposing factors or the early stages of CRC. Also, these biomarkers have the potential to determine the appropriate treatment algorithms by selecting the proper chemotherapeutic agents that can induce remission in a broad spectrum of patients. This review throws light on the tumor markers of CRC and their role in early diagnosis and determination of prognosis and the suitable lines of management of patients with CRC.

Keywords